Literature DB >> 31116487

18 F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE.

Georgios Z Papadakis1,2,3, Georgios C Manikis1, Apostolos H Karantanas1,3, Pablo Florenzano2,4, Ulas Bagci5, Kostas Marias1, Michael T Collins2, Alison M Boyce2.   

Abstract

Fibrous dysplasia (FD) is a mosaic skeletal disorder resulting in fractures, deformity, and functional impairment. Clinical evaluation has been limited by a lack of surrogate endpoints capable of quantitating disease activity. The purpose of this study was to investigate the utility of 18 F-NaF PET/CT imaging in quantifying disease activity in patients with FD. Fifteen consecutively evaluated subjects underwent whole-body 18 F-NaF PET/CT scans, and FD burden was assessed by quantifying FD-related 18 F-NaF activity. 18 F-NaF PET/CT parameters obtained included (i) SUVmax (standardized uptake value [SUV] of the FD lesion with the highest uptake); (ii) SUVmean (average SUV of all 18 F-NaF-positive FD lesions); (iii) total volume of all 18 F-NaF-positive FD lesions (TV); and (iv) total FD lesion activity determined as the product of TV multiplied by SUVmean (TA =  TV ×  SUVmean ) (TA). Skeletal outcomes, functional outcomes, and bone turnover markers were correlated with 18 F-NaF PET/CT parameters. TV and TA of extracranial FD lesions correlated strongly with skeletal outcomes including fractures and surgeries (p values ≤ 0.003). Subjects with impaired ambulation and scoliosis had significantly higher TV and TA values (P < 0.05), obtained from extracranial and spinal lesions, respectively. Craniofacial surgeries correlated with TV and TA of skull FD lesions (P < 0.001). Bone turnover markers, including alkaline phosphatase, N-telopeptides, and osteocalcin, were strongly correlated with TV and TA (P < 0.05) extracted from FD lesions in the entire skeleton. No associations were identified with SUVmax or SUVmean . Bone pain and age did not correlate with 18 F-NaF PET/CT parameters. FD burden evaluated by 18 F-NaF-PET/CT facilitates accurate assessment of FD activity, and correlates quantitatively with clinically-relevant skeletal outcomes.
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ANALYSIS/QUANTITATION OF BONE (OTHER); BIOCHEMICAL MARKERS OF BONE TURNOVER; DISEASES AND DISORDERS OF/RELATED TO BONE (OTHER)

Mesh:

Substances:

Year:  2019        PMID: 31116487      PMCID: PMC6744316          DOI: 10.1002/jbmr.3738

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.390


  28 in total

Review 1.  Molecular mechanisms of bone 18F-NaF deposition.

Authors:  Johannes Czernin; Nagichettiar Satyamurthy; Christiaan Schiepers
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

2.  Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.

Authors:  Christie Lin; Tyler Bradshaw; Timothy Perk; Stephanie Harmon; Jens Eickhoff; Ngoneh Jallow; Peter L Choyke; William L Dahut; Steven Larson; John Laurence Humm; Scott Perlman; Andrea B Apolo; Michael J Morris; Glenn Liu; Robert Jeraj
Journal:  J Nucl Med       Date:  2016-07-21       Impact factor: 10.057

3.  Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.

Authors:  Tae Min Kim; Jin Chul Paeng; In Kook Chun; Bhumsuk Keam; Yoon Kyung Jeon; Se-Hoon Lee; Dong-Wan Kim; Dong Soo Lee; Chul Woo Kim; June-Key Chung; Il Han Kim; Dae Seog Heo
Journal:  Cancer       Date:  2012-12-04       Impact factor: 6.860

4.  Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Authors:  Wolfgang Peter Fendler; Donfack Beauclair Philippe Tiega; Harun Ilhan; Philipp M Paprottka; Volker Heinemann; Tobias F Jakobs; Peter Bartenstein; Marcus Hacker; Alexander Robert Haug
Journal:  J Nucl Med       Date:  2013-05-31       Impact factor: 10.057

5.  Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome.

Authors:  Elizabeth S Hart; Marilyn H Kelly; Beth Brillante; Clara C Chen; Navid Ziran; Janice S Lee; Penelope Feuillan; Arabella I Leet; Harvey Kushner; Pamela G Robey; Michael T Collins
Journal:  J Bone Miner Res       Date:  2007-09       Impact factor: 6.741

6.  Clinical guidelines for the management of craniofacial fibrous dysplasia.

Authors:  J S Lee; E J FitzGibbon; Y R Chen; H J Kim; L R Lustig; S O Akintoye; M T Collins; L B Kaban
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

7.  The surgical management of fibrous dysplasia of bone.

Authors:  Robert P Stanton; Ernesto Ippolito; Dempsey Springfield; Lynn Lindaman; Shlomo Wientroub; Arabella Leet
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

8.  A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.

Authors:  Alison M Boyce; Marilyn H Kelly; Beth A Brillante; Harvey Kushner; Shlomo Wientroub; Mara Riminucci; Paolo Bianco; Pamela G Robey; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-07-17       Impact factor: 5.958

9.  Individualized approach to the surgical management of fibrous dysplasia of the proximal femur.

Authors:  Bas C J Majoor; Andreas Leithner; Michiel A J van de Sande; Natasha M Appelman-Dijkstra; Neveen A T Hamdy; P D Sander Dijkstra
Journal:  Orphanet J Rare Dis       Date:  2018-05-02       Impact factor: 4.123

Review 10.  Fibrous dysplasia for radiologists: beyond ground glass bone matrix.

Authors:  Yevgeniya S Kushchayeva; Sergiy V Kushchayev; Tetiana Y Glushko; Sri Harsha Tella; Oleg M Teytelboym; Michael T Collins; Alison M Boyce
Journal:  Insights Imaging       Date:  2018-11-27
View more
  10 in total

1.  Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.

Authors:  Wouter van der Bruggen; Marlous Hagelstein-Rotman; Lioe-Fee de Geus-Oei; Frits Smit; P D Sander Dijkstra; Natasha M Appelman-Dijkstra; Dennis Vriens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-24       Impact factor: 9.236

Review 2.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

3.  Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.

Authors:  Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2021-11-17       Impact factor: 6.390

Review 4.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

5.  Genotype-Phenotype Correlation in Fibrous Dysplasia/McCune-Albright Syndrome.

Authors:  Maria Zhadina; Kelly L Roszko; Raya E S Geels; Luis F de Castro; Michael T Collins; Alison M Boyce
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

Review 6.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

7.  Regression of fibrous dysplasia in response to denosumab therapy: A report of two cases.

Authors:  Maartje E Meier; Wouter van der Bruggen; Michiel A J van de Sande; Natasha M Appelman-Dijkstra
Journal:  Bone Rep       Date:  2021-04-09

8.  Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.

Authors:  Wouter van der Bruggen; Dennis Vriens; Maartje E Meier; Frits Smit; Elizabeth M Winter; Lioe-Fee de Geus-Oei; Natasha M Appelman-Dijkstra
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

9.  PET Imaging of Phosphodiesterase-4 Identifies Affected Dysplastic Bone in McCune-Albright Syndrome, a Genetic Mosaic Disorder.

Authors:  Lora D Weidner; Yuichi Wakabayashi; Louise A Stolz; Michael T Collins; Lori Guthrie; Milalynn Victorino; Joyce Chung; William Miller; Sami S Zoghbi; Victor W Pike; Masahiro Fujita; Robert B Innis; Alison M Boyce
Journal:  J Nucl Med       Date:  2020-04-13       Impact factor: 11.082

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.